• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发作性睡病与大流行性流感的故事:真相能被揭开吗?

The narcolepsy-pandemic influenza story: can the truth ever be unraveled?

作者信息

Sturkenboom Miriam C J M

机构信息

Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.

出版信息

Vaccine. 2015 Jun 8;33 Suppl 2:B6-B13. doi: 10.1016/j.vaccine.2015.03.026.

DOI:10.1016/j.vaccine.2015.03.026
PMID:26022571
Abstract

A safety signal around Pandemrix, an AS03 adjuvanted influenza A(H1N1) pdm09 vaccine potentially causing narcolepsy in children and adolescents became public in August 2010, long after cessation of the influenza A(H1N1) pdm09 campaigns in Europe. The signal originated from Finland and Sweden, two countries with school based pandemic vaccination campaigns, with high vaccine coverage, and vaccinations being provided at the peak of the circulating wild virus. Since the announcement awareness grew in Europe, with extensive public media dissemination and regulatory actions. This resulted in a steep increase in the spontaneous reports of exposed cases, a decrease in diagnostic lag times of this rare, underdiagnosed disease and finally victim compensation. The signaling countries conducted rapid risk assessment studies to quantify the signal to the best of their abilities, in the midst of the public awareness, most of which could not distinguish between a vaccine and an awareness effect. Due to the strong but variable associations from the epidemiological studies, the search for biological mechanisms started. Currently it is not yet understood how Pandemrix might cause narcolepsy, and whether it would be specific to Pandemrix. The paper describes the current evidence and puts forward the questions that remain to be answered, which are relevant for future pandemic preparedness when adjuvants may be used for dose sparing.

摘要

2010年8月,一种AS03佐剂的甲型H1N1pdm09流感疫苗“盼尔来福”(Pandemrix)可能导致儿童和青少年发作性睡病的安全信号被公开,此时欧洲甲型H1N1pdm09流感疫苗接种活动早已结束。该信号源自芬兰和瑞典,这两个国家开展了以学校为基础的大流行疫苗接种活动,疫苗接种率高,且在野生病毒传播高峰期进行接种。自该信号公布以来,随着广泛的公共媒体传播和监管行动,欧洲的关注度不断提高。这导致暴露病例的自发报告急剧增加,这种罕见的、诊断不足的疾病的诊断滞后时间缩短,最终实现了受害者赔偿。在公众关注度较高的情况下,发出信号的国家尽最大能力开展了快速风险评估研究,以量化该信号,其中大多数研究无法区分疫苗和关注度的影响。由于流行病学研究的关联很强但存在差异,因此开始寻找生物学机制。目前尚不清楚“盼尔来福”如何导致发作性睡病,以及它是否是“盼尔来福”所特有的。本文描述了当前的证据,并提出了有待回答的问题,这些问题对于未来在可能使用佐剂来节省剂量的大流行防范工作具有相关性。

相似文献

1
The narcolepsy-pandemic influenza story: can the truth ever be unraveled?发作性睡病与大流行性流感的故事:真相能被揭开吗?
Vaccine. 2015 Jun 8;33 Suppl 2:B6-B13. doi: 10.1016/j.vaccine.2015.03.026.
2
The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns.欧洲嗜睡症的发病率:在甲型 H1N1pdm09 流感大流行及疫苗接种运动之前、期间和之后。
Vaccine. 2013 Feb 6;31(8):1246-54. doi: 10.1016/j.vaccine.2012.12.015. Epub 2012 Dec 16.
3
Narcolepsy and Pandemic Influenza Vaccination: What We Need to Know to be Ready for the Next Pandemic.发作性睡病与大流行性流感疫苗接种:为应对下一次大流行,我们需要了解哪些信息
Pediatr Infect Dis J. 2019 Aug;38(8):873-876. doi: 10.1097/INF.0000000000002398.
4
Pandemrix™ and narcolepsy: A critical appraisal of the observational studies.潘得立克(Pandemrix™)与发作性睡病:对观察性研究的批判性评估
Hum Vaccin Immunother. 2016;12(1):187-93. doi: 10.1080/21645515.2015.1068486. Epub 2015 Sep 17.
5
Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A/H1N1 influenza vaccine (Pandemrix) during the 2009 H1N1 influenza pandemic.随着时间的推移,接种 AS03 佐剂大流行性 A/H1N1 流感疫苗(Pandemrix)后发生嗜睡症的风险变化,以及接种疫苗后发病日期定义的影响,在 2009 年 H1N1 流感大流行期间。
Pharmacoepidemiol Drug Saf. 2019 Aug;28(8):1045-1053. doi: 10.1002/pds.4788. Epub 2019 May 6.
6
A coordinated cross-disciplinary research initiative to address an increased incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden.一项协调跨学科的研究计划,旨在解决瑞典 2009-2010 年 Pandemrix 疫苗接种计划后嗜睡症发病率上升的问题。
J Intern Med. 2015 Oct;278(4):335-53. doi: 10.1111/joim.12391. Epub 2015 Jun 30.
7
Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study.台湾、加拿大和欧洲的嗜睡症诊断发病率:使用统计模拟评估 SOMNIA 研究中在人群水平上快速评估潜在安全问题的方法。
PLoS One. 2018 Oct 17;13(10):e0204799. doi: 10.1371/journal.pone.0204799. eCollection 2018.
8
Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting.会议报告:发作性睡病与大流行性流感疫苗接种——在下一次大流行之前我们已知和需要了解的情况?来自第二届国际发作性睡病研究学会会议的报告
Biologicals. 2019 Jul;60:1-7. doi: 10.1016/j.biologicals.2019.05.005. Epub 2019 May 23.
9
Risk of Narcolepsy after AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine in Adults: A Case-Coverage Study in England.成人接种AS03佐剂大流行甲型H1N1 2009流感疫苗后患发作性睡病的风险:英格兰的一项病例对照研究。
Sleep. 2016 May 1;39(5):1051-7. doi: 10.5665/sleep.5752.
10
Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment.发作性睡病与佐剂季节性流感 A(H1N1)2009 疫苗——多国评估。
Vaccine. 2018 Oct 1;36(41):6202-6211. doi: 10.1016/j.vaccine.2018.08.008. Epub 2018 Aug 16.

引用本文的文献

1
Naringenin as a phytogenic adjuvant systematically enhances the protective efficacy of H9N2 inactivated vaccine through coordinated innate-adaptive immune priming in chickens.柚皮素作为一种植物源佐剂,通过协调鸡体内先天性-适应性免疫启动,系统性增强H9N2灭活疫苗的保护效力。
Poult Sci. 2025 Aug;104(8):105257. doi: 10.1016/j.psj.2025.105257. Epub 2025 May 2.
2
Advances in Adjuvanted Influenza Vaccines.佐剂流感疫苗的进展
Vaccines (Basel). 2023 Aug 21;11(8):1391. doi: 10.3390/vaccines11081391.
3
The immunopathogenesis of narcolepsy type 1.
1 型发作性睡病的免疫发病机制。
Nat Rev Immunol. 2024 Jan;24(1):33-48. doi: 10.1038/s41577-023-00902-9. Epub 2023 Jul 3.
4
Narcolepsy and H1N1 influenza immunology a decade later: What have we learned?嗜睡症与 H1N1 流感免疫:十年后,我们有何新认识?
Front Immunol. 2022 Oct 12;13:902840. doi: 10.3389/fimmu.2022.902840. eCollection 2022.
5
Relief After COVID-19 Vaccination: A Doubtful or Evident Outcome?新冠疫苗接种后的缓解:是可疑还是明确的结果?
Front Med (Lausanne). 2022 Jan 10;8:800040. doi: 10.3389/fmed.2021.800040. eCollection 2021.
6
Reassessment of the risk of narcolepsy in children in England 8 years after receipt of the AS03-adjuvanted H1N1 pandemic vaccine: A case-coverage study.英格兰儿童接种 AS03 佐剂 H1N1 大流行疫苗 8 年后对嗜睡症风险的再评估:病例覆盖研究。
PLoS Med. 2020 Sep 14;17(9):e1003225. doi: 10.1371/journal.pmed.1003225. eCollection 2020 Sep.
7
Suspicions of possible vaccine harms must be scrutinised openly and independently to ensure confidence.对疫苗可能造成的危害的怀疑必须进行公开且独立的审查,以确保公众信心。
NPJ Vaccines. 2020 Jul 6;5(1):55. doi: 10.1038/s41541-020-0202-9. eCollection 2020.
8
Differences in clinical and genetic characteristics between early- and late-onset narcolepsy in a Han Chinese cohort.中国汉族人群早发型和晚发型发作性睡病临床及遗传特征的差异
Neural Regen Res. 2020 Oct;15(10):1887-1893. doi: 10.4103/1673-5374.280322.
9
Physiology of gangliosides and the role of antiganglioside antibodies in human diseases.神经节苷脂的生理学和抗神经节苷脂抗体在人类疾病中的作用。
Cell Mol Immunol. 2020 Apr;17(4):313-322. doi: 10.1038/s41423-020-0388-9. Epub 2020 Mar 9.
10
Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting.会议报告:发作性睡病与大流行性流感疫苗接种——在下一次大流行之前我们已知和需要了解的情况?来自第二届国际发作性睡病研究学会会议的报告
Biologicals. 2019 Jul;60:1-7. doi: 10.1016/j.biologicals.2019.05.005. Epub 2019 May 23.